A Bayesian Network View on Nested Effects Models

Por Zeller, Cordula, Fröhlich, Holger, Tresch, Achim
Publicado em 2008

Safety and Tolerability of Empagliflozin in Patients with Type 2 Diabetes: Pooled Analysis of Phase I–III Clinical Trials

Por Kohler, Sven, Zeller, Cordula, Iliev, Hristo, Kaspers, Stefan
Publicado no Adv Ther (2017)

Rationale, design and baseline characteristics of a 4-year (208-week) phase III trial of empagliflozin, an SGLT2 inhibitor, versus glimepiride as add-on to metformin in patients wi...

Por Ridderstråle, Martin, Svaerd, Robbyna, Zeller, Cordula, Kim, Gabriel, Woerle, Hans J, Broedl, Uli C
Publicado em 2013

Early benefits of empagliflozin in patients with or without heart failure: findings from EMPA‐REG OUTCOME

Por Pellicori, Pierpaolo, Ofstad, Anne Pernille, Fitchett, David, Zeller, Cordula, Wanner, Christoph, George, Jyothis, Zinman, Bernard, Brueckmann, Martina, Lindenfeld, JoAnn
Publicado no ESC Heart Fail (2020)

Comparison of Adipose Distribution Indices with Gold Standard Body Composition Assessments in the EMPA-REG H2H SU Trial: A Body Composition Sub-Study

Por Neeland, Ian J., McGuire, Darren K., Eliasson, Björn, Ridderstråle, Martin, Zeller, Cordula, Woerle, Hans J., Broedl, Uli C., Johansen, Odd Erik
Publicado no Diabetes Ther (2015)

Correction to: Comparison of Adipose Distribution Indices with Gold Standard Body Composition Assessments in the EMPA-REG H2H SU Trial: A Body Composition Sub-Study

Por Neeland, Ian J., McGuire, Darren K., Eliasson, Björn, Ridderstråle, Martin, Zeller, Cordula, Woerle, Hans J., Broedl, Uli C., Johansen, Odd Erik
Publicado no Diabetes Ther (2018)

Design of a prospective patient‐level pooled analysis of two parallel trials of empagliflozin in patients with established heart failure

Por Packer, Milton, Butler, Javed, Filippatos, Gerasimos, Zannad, Faiez, Ferreira, Joao Pedro, Zeller, Cordula, Brueckmann, Martina, Jamal, Waheed, Pocock, Stuart J., Anker, Stefan D.
Publicado no Eur J Heart Fail (2020)

Rationale and design of the EMPERIAL‐Preserved and EMPERIAL‐Reduced trials of empagliflozin in patients with chronic heart failure

Por Abraham, William T., Ponikowski, Piotr, Brueckmann, Martina, Zeller, Cordula, Macesic, Hemani, Peil, Barbara, Brun, Michèle, Ustyugova, Anastasia, Jamal, Waheed, Salsali, Afshin, Lindenfeld, JoAnn, Anker, Stefan D.
Publicado no Eur J Heart Fail (2019)

Safety and tolerability of empagliflozin in East Asian patients with type 2 diabetes: Pooled analysis of phase I–III clinical trials

Por Yabe, Daisuke, Yasui, Atsutaka, Ji, Linong, Lee, Moon‐Kyu, Ma, Ronald Ching Wan, Chang, Tien‐Jyun, Okamura, Tomoo, Zeller, Cordula, Kaspers, Stefan, Lee, Jisoo, Kohler, Sven, Seino, Yutaka
Publicado no J Diabetes Investig (2018)

Cardiac and Kidney Benefits of Empagliflozin in Heart Failure Across the Spectrum of Kidney Function: Insights From EMPEROR-Reduced

Por Zannad, Faiez, Ferreira, João Pedro, Pocock, Stuart J., Zeller, Cordula, Anker, Stefan D., Butler, Javed, Filippatos, Gerasimos, Hauske, Sibylle Jenny, Brueckmann, Martina, Pfarr, Egon, Schnee, Janet, Wanner, Christoph, Packer, Milton
Publicado no Circulation (2020)

Effect of Empagliflozin on the Clinical Stability of Patients With Heart Failure and a Reduced Ejection Fraction: The EMPEROR-Reduced Trial

Por Packer, Milton, Anker, Stefan D., Butler, Javed, Filippatos, Gerasimos, Ferreira, João Pedro, Pocock, Stuart J., Carson, Peter, Anand, Inder, Doehner, Wolfram, Haass, Markus, Komajda, Michel, Miller, Alan, Pehrson, Steen, Teerlink, John R., Brueckmann, Martina, Jamal, Waheed, Zeller, Cordula, Schnaidt, Sven, Zannad, Faiez
Publicado no Circulation (2020)